Form 4: LivaNova PLC Director, Brooke Story, Reports Share Transactions

Director Brooke Story reports acquisition and disposal of LivaNova PLC ordinary shares related to restricted stock units.

Summary

• On June 15, 2024, Brooke Story, a director of LivaNova PLC, reported transactions involving the company's ordinary shares.
• 2,680 ordinary shares were acquired upon settlement of restricted stock units (RSUs) at a price of $0.
• 584 ordinary shares were disposed of to satisfy tax liability at a price of $52.68.
• Following these transactions, Story directly owns 3,476 ordinary shares.
• Additionally, Story was granted 3,416 RSUs vesting on June 15, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transactions are related to standard RSU vesting and tax obligations. There is no indication of unusual activity or significant concern.

Positives

• The acquisition of shares through RSU settlement indicates confidence in the company's future performance.

Future Outlook

The reporting person holds RSUs that will vest in the future, subject to continued service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Companies like Medtronic and Boston Scientific also have similar insider transaction reporting requirements.
• The vesting schedules and terms of RSUs are generally comparable across the medical device industry, often tied to continued employment and company performance.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders as they are part of standard executive compensation practices.

Key Dates